Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs State Street PDR S&P Retail ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $152.76 (market cap $10.11B), while State Street PDR S&P Retail ETF trades at $83.62 (market cap $389.66M). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 25.9× State Street PDR S&P Retail ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 37 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| XBI | XRT | |
|---|---|---|
Market Cap | $10.11B | $389.66M |
Volume | 12,903,266 | 4,275,820 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $169.55 | $92.35 |
52-Week Low | $104.99 | $77.28 |
Typical Hold Time | 37 Days | 44 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
XRT (SPDR S&P Retail ETF) trades at $83.45, up 0.65% with a bullish technical signal despite bearish moving averages. The ETF faces mixed sentiment as retail sales show volatility, with August's 1.2% rebound contrasting July's 0.6% decline. Key resistance sits at $85, while RSI-6 at 84.45 indicates potential overbought conditions. Recent news highlights holiday sales projections exceeding $1 trillion but concerns over consumer spending shifts toward value-oriented purchases.
Outlook remains cautious amid macroeconomic pressures; higher interest rates and inflation weigh on consumer sentiment, with analysts expecting continued underperformance versus broader markets. The ETF's equal-weight approach provides diversification, but selective consumer spending patterns and oil price volatility pose near-term risks. Investment appeal hinges on holiday season performance and Federal Reserve policy direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
